Core Viewpoint - Eli Lilly's GLP-1 drug Tirzepatide (brand name: Mounjaro) has officially launched in China, achieving significant market demand with a 300% increase in pre-launch reservations and selling out within 3 seconds of its release [2][3]. Sales Performance - In the first three quarters of 2024, Tirzepatide generated $11 billion in total sales for Eli Lilly, with $3.113 billion in Q3 alone for the diabetes version and $1.258 billion for the weight loss version [3]. - The sales figures indicate a strong market presence, with expectations that Tirzepatide may surpass its competitor Semaglutide in popularity [2][3]. Market Dynamics - The launch of Tirzepatide provides patients with an alternative to Semaglutide, as individual responses to these medications can vary, allowing for personalized treatment options [3]. - High-profile endorsements, such as from Elon Musk, have contributed to the drug's popularity, as he transitioned from using Semaglutide to Tirzepatide, citing fewer side effects and greater effectiveness [4][7]. Clinical Efficacy - Tirzepatide's unique dual-target design (GIPR/GLP-1R) has shown superior weight loss results in clinical trials, with patients losing an average of 15.4% to 22.9% of their body weight compared to only 2.1% in the placebo group [10][12]. - In the SURMOUNT-5 trial, patients treated with Tirzepatide lost an average of 50.3 pounds (approximately 22.8 kg), significantly outperforming the active control group [15]. Safety Profile - Approximately 80% of Tirzepatide users reported experiencing at least one side effect, primarily gastrointestinal issues such as nausea and diarrhea, similar to those reported with Semaglutide [16][18]. - The incidence of nausea was reported at 33% for Tirzepatide users, compared to 44% for Semaglutide, indicating a potentially lower frequency of side effects with Tirzepatide [16][18].

Core Viewpoint - Eli Lilly's experimental weight loss drug, eloralintide, shows promising results in initial studies with minimal side effects, indicating progress in the competitive weight loss treatment market [2][5]. Group 1: Drug Efficacy and Research - In a three-month trial, some participants lost over 11% of their body weight, with weight loss ranging from 2.6% to 11.3% [2][5]. - The study involved 100 participants who received different doses of eloralintide or a placebo, with gastrointestinal side effects being relatively mild [5]. - Approximately 10% of participants experienced diarrhea, and 8% reported vomiting, but detailed risk-benefit analysis by dosage was not provided [5]. Group 2: Market Context and Competition - The demand for more tolerable and convenient weight loss medications is increasing, prompting pharmaceutical companies to accelerate their efforts in this rapidly growing market [5]. - Eli Lilly's Zepbound and Novo Nordisk's Wegovy currently dominate the market, but new generation drugs are gaining attention [5]. - Roche and Zealand Pharma entered a $5.3 billion collaboration to develop petrelintide, which has shown early promise, while AbbVie has also invested in this sector [6]. Group 3: Future Developments - Eli Lilly is conducting single-agent tests of eloralintide and exploring its use in combination with Zepbound, similar to Novo Nordisk's approach with CagriSema [7]. - Eli Lilly has several promising next-generation products in late-stage development, including an oral drug named orforglipron and a more potent experimental injectable [6].

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 近日，"国家喊你减肥"成为网络热议焦点，卫健委主任雷海潮在两会期间的公开倡议引发广泛关注。表面上看这是一次幽默的"喊话"，但实际 上，它背后是一项关系到全民健康的重要举措。究竟是什么让国家如此关注体重问题？这场全民参与的"减重行动"将会给我们的生活带来哪些 新变化？ ▍肥胖：一场被低估的公共健康危机 1. 触目惊心的数据 令人震惊的数字显示，中国成年人超重率已高达34.3%，肥胖率达到16.4%，而青少年的肥胖问题也在持续上升。如果不采取有效措施，预计到 2030年，成年人超重和肥胖的比例或将突破70%。更值得警惕的是，肥胖与200多种疾病密切相关，包括糖尿病、心脑血管疾病和癌症等，慢 性病造成的死亡人数已超过总死亡的80%。 2. 社会和经济层面的隐形压力 肥胖不仅会缩短个人寿命，还会增加医保负担，降低整体劳动力效率。数据显示，慢性病占我国疾病总负担的七成以上，每年因肥胖相关疾病 产生的医疗费用高达数千亿元。 ▍国家亲自下场：从治病到"治未病"的转型 ...

整理 | GLP1减重宝典内容团队 替尔泊肽是一款近年来在糖尿病治疗和体重管理中备受关注的药物。 替尔泊肽通过模拟体内天然GLP-1激素的作用，帮助调节血糖水平、促进 胰岛素分泌、抑制食欲并延缓胃排空。 由于其独特的作用机制，替尔泊肽不仅在2型糖尿病治疗中表现出色，还在肥胖症的治疗中展现出巨大 潜力。 然而，并非所有患者都适合使用替尔泊肽。 本文将从适应症、禁忌症、患者特征、不良反应、未来发展方向及疗效等多个角度，全面探 讨什么样的人适合替尔泊肽。 ▍替尔泊肽的作用机制与临床优势 替尔泊肽通过激活GIP/GLP-1受体发挥作用，主要机制包括： 促进胰岛素分泌 ：替尔泊肽在血糖升高时刺激胰岛β细胞分泌胰岛素，从而降低血糖。 抑制胰高血糖素分泌 ：减少胰高血糖素的释放，进一步降低血糖水平。 延缓胃排空 ：减缓食物从胃进入小肠的速度，增加饱腹感，减少食物摄入。 抑制食欲 ：作用于中枢神经系统，减少饥饿感，有助于体重管理。 这些机制使替尔泊肽在2型糖尿病和肥胖症的治疗中具有显著优势，尤其是对于需要同时控制血糖和体重的患者。 点击关注，追踪最新GLP-1资讯 ▍替尔泊肽的主要适应症 1. 2型糖尿病患者 替尔泊肽是2型 ...

Core Viewpoint - GLP-1 (glucagon-like peptide-1) plays a crucial role in regulating blood sugar and controlling weight, with significant advancements in the development of GLP-1 drugs globally, particularly focusing on oral formulations like Rybelsus [2][4][6] Group 1: GLP-1 Overview - GLP-1 is secreted by intestinal L cells and helps in slowing gastric motility, prolonging gastric emptying time, and effectively suppressing appetite [2] - Notable GLP-1 drugs include Semaglutide (Ozempic for diabetes, Wegovy for weight loss, and Rybelsus as the first oral GLP-1 receptor agonist) and Tirzepatide (Mounjaro) [2][4] Group 2: Rybelsus Advantages - Rybelsus offers convenience as an oral medication, eliminating the need for refrigeration and improving patient adherence due to accurate dosing [4] - The formulation includes Semaglutide and an absorption enhancer (SNAC), which increases the bioavailability of the drug by approximately 100 times [4] Group 3: Clinical Research and Efficacy - The global Phase III clinical trial PIONEER involved 11,505 patients and confirmed the efficacy and safety of oral Semaglutide, showing significant reductions in blood sugar and weight [6] - In China, the HbA1c target achievement rate for newly diagnosed type 2 diabetes patients using Rybelsus monotherapy reached 92.3% [6] Group 4: Comparison of Formulations - Ozempic (injection for diabetes) and Wegovy (injection for weight loss) have similar efficacy profiles to Rybelsus, which is an oral formulation [7][8][9] - Clinical trials indicate that Rybelsus can potentially replace injection forms without dosage adjustments, providing a "pain-free" weight loss option [12] Group 5: Weight Loss Outcomes - In clinical trials, Rybelsus demonstrated significant weight loss, with a 68-week study showing an average weight reduction of 17.4% (18.34 kg) in obese patients [10] - The OASIS 4 study indicated that patients on 25 mg oral Semaglutide lost an average of 13.6% (14.4 kg) of their body weight over 64 weeks [16] Group 6: Safety and Tolerability - While oral Semaglutide shows similar efficacy to injection forms, higher doses (25 mg and 50 mg) may be required to achieve comparable weight loss results [14][15] - Safety concerns include a 14% incidence of "skin sensation abnormalities" at the 50 mg dose, which were not reported in injection forms [15]

Core Viewpoint - The article discusses the safety of GLP-1 receptor agonists (GLP-1RAs), particularly regarding their potential link to thyroid cancer, based on a recent large-scale study that provides reassuring evidence for patients and healthcare providers [1][2][3]. Group 1: Background on GLP-1RAs - GLP-1 receptor agonists, such as semaglutide and liraglutide, are gaining attention for their dual benefits of lowering blood sugar and aiding weight loss among diabetes and obesity patients [1]. - Concerns have been raised about the potential risk of thyroid cancer associated with these medications, leading to confusion among doctors and patients [2][6]. Group 2: Research Findings - A significant study published in June 2025 in the journal "Diabetes Care" analyzed data from over 460,000 type 2 diabetes patients who were first-time users of GLP-1RAs, comparing them with patients using other common second-line diabetes medications [3][7]. - The study employed rigorous methodologies, including adjustments for 90,000 variables and a one-year delay analysis to enhance the reliability of the results [7]. Group 3: Results and Implications - The study found no significant increase in thyroid cancer risk among GLP-1RA users compared to those on other medications, with the risk ratio close to 1 and not statistically significant [8]. - The incidence rate of thyroid cancer in the GLP-1RA group was approximately 0.88 to 1.03 per 1,000 person-years, comparable to the control group, indicating no elevated risk [8]. Group 4: Recommendations - The findings suggest that patients currently using or considering GLP-1RAs can be reassured about the thyroid safety of these medications [9]. - While the study has limitations, such as the exclusion of some European data and the retrospective nature of the analysis, it remains one of the most comprehensive studies on this topic to date [10][12]. Group 5: Conclusion - The research serves as an important reference for healthcare providers in making medication decisions and alleviating patient concerns regarding cancer risks associated with GLP-1RAs [11]. - Ongoing accumulation of long-term data will further enhance understanding of the safety profile of these drugs [12].

Core Viewpoint - The article emphasizes the urgent need for a comprehensive approach to weight management in China, highlighting the alarming obesity crisis and the necessity for innovative solutions that integrate technology, policy, and community efforts [3][5][18]. Group 1: Obesity Crisis and Health Implications - By 2025, the overweight rate among Chinese adults is projected to reach 34.3%, with obesity rates at 16.4%, and a 12-fold increase in youth obesity over the past 15 years [3]. - If no effective measures are taken, by 2030, adult overweight and obesity rates could soar to 70.5%, while youth rates may hit 31.8% [3]. - Obesity is linked to over 200 diseases, leading to annual medical expenditures exceeding 240 billion yuan [5]. Group 2: Comprehensive Health Ecosystem Development - The National Health Commission's "National Fitness Plan" promotes a dual focus on muscle gain and fat loss, moving away from the sole reliance on BMI for health assessments [6]. - Innovative products, such as a patented CLA+ whey protein blend, have shown promising results in trials, with users gaining an average of 2.3 kg of muscle and losing 4.7 kg of fat over three months [6]. - The "Metabolic Map" project aims to utilize wearable devices to monitor metabolic health indicators, enhancing personalized health management [7]. Group 3: New Approaches to Weight Management - Community health initiatives in regions like Guangdong and Zhejiang are incorporating gut microbiome testing into routine health checks to address obesity linked to microbiome imbalances [8]. - A combination of prebiotics and postbiotics has been developed to promote beneficial gut bacteria, resulting in users experiencing a 5 cm reduction in waist circumference and a 23% improvement in skin elasticity [8]. - The integration of skin-tightening treatments in weight loss programs is gaining traction, with high satisfaction rates reported post-treatment [9]. Group 4: Addressing Market Challenges - The weight loss market is plagued by misinformation, with 40% of products exaggerating their effectiveness, leading to consumer confusion and potential health risks [12]. - There is a significant gap in obesity treatment resources, with less than 15% of primary hospitals adhering to obesity treatment guidelines and a shortage of specialized medical professionals [13]. Group 5: Future of Weight Management - The future of weight management is expected to leverage advanced technologies such as AR body fat scanning and AI-driven personalized plans, making weight loss more intelligent and effective [17]. - A collaborative approach involving government, businesses, and communities is essential to create a supportive environment for health initiatives [17].

整理 | GLP1减重宝典内容团队 尽管财务细节尚未公开，协议包括一笔未披露的首付款、股权投资以及基于阶段性成果的激励。根据协议内容，礼来将获得对Juvena研发出的 领先候选药物的独家开发权；若项目进入后期阶段，礼来将主导其研究、开发与商业化进程。 在刚刚宣布合作开发长效GLP-1受体激动剂后，礼来（Eli Lilly）又达成了一项新的生物技术合作协议，进一步拓展其在减重治疗领域的影响 力。此次，这家制药巨头与Juvena Therapeutics携手，拟通过高达6.5亿美元的里程碑支付，共同开发有助于维持肌肉质量与功能的新疗法。 这是礼来在一周内签署的第二份重要合作协议。此前，公司刚与瑞典企业Camurus达成合作，最高承诺金额达8.7亿美元，其中包括2.9亿美元的 预付款。该协议赋予礼来使用Camurus专有长效药物递送技术的权利，以开发长效版本的GLP-1及其他促胰素类候选药物。 通过此次与Juvena的合作，礼来将接入其AI驱动的JuvNET筛选平台。该平台可映射由再生干细胞分泌的蛋白质的治疗潜力，用于发现能改善肌 肉健康与身体成分的新型药物候选分子——这在减重治疗中尤为关键。 目前尚不清楚此次合作 ...

整理 | GLP1减重宝典内容团队 Johann Hari写了一本名为《神奇药物》（Magic Pill）的新书。他是一名住在伦敦和拉斯维加斯的记者。 你最担心的潜在风险是什么？ 司美格鲁肽用于肥胖患者只有两年多一点的时间。我们不知道服用它们的长期影响。有人担心它们可能会产生一些我们不知道的长期影响。 具体是什么让你烦恼？ 2023 年，Hari 体重 203 磅（180斤），体脂率为 32%，医生给他开了这种药来减肥。 Hari 的祖父 44 岁时死于心脏病，他的叔叔 60 多岁，他的父亲 70 多岁时接受了四次心脏搭桥手术。Hari 没有糖尿病，他对减肥药持谨慎态 度，因为他知道过去的选择"总是以灾难告终"，他说。但使用 Ozempic 减肥似乎是降低自身心脏病风险的一种方法。 第一次服药几天后，他就注意到了这种药物的效果。"我醒来后想，'有点奇怪。那是什么？'我不知道那是什么。然后我突然意识到我醒了，但 我不饿。我以前从来没有发生过这种事。从那时起，我的食欲就急剧下降。我比以前饿得多。我很快就感到很饱。" 哈里最终通过服用 Ozempic 和Wegovy 减掉了 42 磅（38斤）。在他的新书《神奇药物 ...

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 在今年全国两会上，国家卫生健康委主任雷海潮用7分钟时间详细介绍了"体重管理年"三年行动计划，旨在推动全社会树立体重管理意识，养成健康饮 食和积极锻炼的良好生活方式，真正实现全民重视体重、科学管理体重的目标。 ▍普通人：管住嘴，迈开腿，养成好习惯 《中国居民营养与慢性病状况报告（2020年）》数据显示，2018年我国成年人的超重率为34.3%，肥胖率为16.4%。国家卫生健康委近日发布的《体重 管理指导原则（2024年版）》也提到，相关研究预测，如果不加以有效控制，到2030年我国成人超重和肥胖率将升至70.5%，儿童超重和肥胖率也可能 达到31.8%。 对普通人来说，管理体重其实并不复杂，关键在于坚持做好日常生活中的细节，同时也可以寻求专业医疗机构的帮助和建议。 首先，合理控制每日热量摄入非常重要。可以根据自己的年龄、性别和日常活动量，初步估算出所需的热量，然后有针对性地安排饮食结构。 需要注意的是，控制热量并不等同于盲目节食，而是要保证营养全面均衡。 ...